(2R,6R)-hydroxynorketamine improves PTSD-associated behaviors and structural plasticity via modulating BDNF-mTOR signaling in the nucleus accumbens

Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants

Ronald S. Duman, George K. Aghajanian, Gerard Sanacora et al. · Nature Medicine · 2016 · 1.6K citations

Synaptic Plasticity, Psychiatry, Medicine +14

NMDAR inhibition-independent antidepressant actions of ketamine metabolites

Panos Zanos, Ruin Moaddel, Patrick J. Morris et al. · Nature · 2016 · 1.5K citations · Full text

Psychiatry, Medicine, Psychopharmacology +7

It Is Time to Address the Crisis in the Pharmacotherapy of Posttraumatic Stress Disorder: A Consensus Statement of the PTSD Psychopharmacology Working Group

John H. Krystal, Lori L. Davis, Thomas C. Neylan et al. · Biological Psychiatry · 2017 · 262 citations

Psychotherapy, Psychiatry, Comorbid Psychiatric Disorder +8

Activity-dependent brain-derived neurotrophic factor signaling is required for the antidepressant actions of (2<i>R</i>,6<i>R</i>)-hydroxynorketamine

Kenichi Fukumoto, Manoela V. Fogaça, Rong-Jian Liu et al. · Proceedings of the National Academy of Sciences · 2018 · 180 citations · Full text

Antidepressant-relevant concentrations of the ketamine metabolite (2 <i>R</i> ,6 <i>R</i> )-hydroxynorketamine do not block NMDA receptor function

Eric W. Lumsden, Timothy A. Troppoli, Scott J. Myers et al. · Proceedings of the National Academy of Sciences · 2019 · 151 citations · Full text